This week on “In Focus,” we explore the growing biotechnology industry here in Wisconsin. From established companies like Verona-based Epic Systems, to other companies with big plans for Wisconsin, like Eli Lilly, the sector continues to grow. ...
Insights from artificial intelligence could eventually transform drug development, if the quality and quantity of biological and chemical data can be improved....
Drugs can't stop Alzheimer's disease yet. But sometimes, they can slow it down....
In 2020, Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now marketed as Leqembi....
Odds in phase II studies are significantly better than for phase I trials....
Dr. Sara McCoy, a rheumatologist in the Department of Medicine, is one of the nation’s leading experts on Sjögren’s disease, an autoimmune disorder that affects moisture-producing glands in the eyes, mouth and other parts of the body....
Betsy Nugent will retire from her position as chief clinical research officer at UW Health and the UW School of Medicine and Public Health on March 3....
The change could leave research institutions like UW–Madison scrambling to find millions of dollars from other sources to support labs, students and staff....
Researchers at the University of Wisconsin-Madison, one of the nation's top research institutions, are wary of potential cuts to funding under the Trump administration that they warn could slow their work and delay new treatments for cancer and other diseases....
Clinical trials for rare conditions are inherently small, yet investigators often find it challenging to meet minimum enrollment requirements. A common reason is that patients are turned away for not having a definitive diagnosis, but that’s something we can improve upon....
